Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-07T15:06:37.695Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment Adherence and Long-Term Outcomes

Published online by Cambridge University Press:  07 November 2014

John M. Kane
John M. Kane*
Affiliation:
Dr. Kane is vice president for Behavioral Health Services at the North Shore-Long Island Jewish Health System and chairman of the Department of Psychiatry at the, Zucker Hillside Hospital, in Glen Oaks, New York
*
John M. Kane, MD, The Zucker Hillside Hospital, 75-59 263 St, Glen Oaks, NY 11004; Tel: 718-470-8141; Fax: 718-343-7739; E-mail: psychiatry@lij.edu.
Get access Rights & Permissions [Opens in a new window]

Abstract

The successful management of schizophrenia is an enormous public health issue. Although antipsychotic medications can be very helpful in reducing rates of relapse and rehospitalization, nonadherence to medication is a frequent cause of exacerbations in psychopathology, psychotic relapse, and rehospitalization. Relapses can have devastating consequences in a variety of clinical and functional domains. Nonadherence can result from a variety of factors that vary from patient to patient and vary over time in individual patients. A number of strategies have been developed to assess and facilitate adherence. The first critical step is clinician awareness of the scope of the problem and consideration of appropriate strategies to address it.

Type
Research Article
Information
CNS Spectrums , Volume 12 , Issue S17 , 2007 , pp. 21 - 26
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Robinson, DG, Woerner, MG, Delman, HM, Kane, JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull. 2005;31(3):705–722.CrossRefGoogle ScholarPubMed
2.Robinson, D, Woerner, M, Alvir, J, et al.Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3): 241–247.CrossRefGoogle ScholarPubMed
3.Robinson, DG, Woerner, MG, Alvir, JM, Bilder, RM, Hinrichsen, GA, Lieberman, JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57(2-3):209–219.CrossRefGoogle ScholarPubMed
4.Coldham, EL, Addington, J, Addington, D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286–290.Google Scholar
5.Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909.Google Scholar
6.Weiden, PJ, Miller, AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001;7(1):41–47.CrossRefGoogle ScholarPubMed
7.Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886–891.Google Scholar
8.Valenstein, M, Copeland, LA, Blow, FC, et al.Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630–639.CrossRefGoogle ScholarPubMed
9.Dolder, CR, Lacro, JP, Dunn, LB, Jeste, DV. Antipsychotic medicine adherence: Is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159(1):103–108.Google Scholar
10.Leucht, S, Barnes, TR, Kissling, W, Engel, RR, Correll, C, Kane, JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209–1222.Google Scholar
11.Lieberman, JA, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.Google Scholar
12.Kane, JM, Leucht, S, Carpenter, D, et al.The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5–19.Google ScholarPubMed
13.Osterberg, L, Blaschke, T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.Google Scholar
14.Cramer, JA, Rosenheck, R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196–201.CrossRefGoogle ScholarPubMed
15.Weiden, PJ, Olfson, M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419–429.CrossRefGoogle ScholarPubMed
16.Knapp, M, King, D, Pugner, K, Lapuerta, P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509–516.Google Scholar
17.Hudson, TJ, Owen, RR, Thrush, CR, et al.A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2):211–216.CrossRefGoogle ScholarPubMed
18.Kemp, R, Hayward, P, Applewhaite, G, Everitt, B, David, A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345–349.CrossRefGoogle ScholarPubMed
19.Kemp, R, Kirov, G, Everitt, B, Hayward, P, David, A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry. 1998;172:413–419.CrossRefGoogle ScholarPubMed
20.O'Donnell, C, Donohoe, G, Sharkey, L, et al.Compliance therapy: a randomised controlled trial in schizophrenia. BMJ. 2003;327(7419):834.CrossRefGoogle ScholarPubMed
21.Byerly, MJ, Fisher, R, Carmody, T, Rush, AJ. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66(8):997–1001.CrossRefGoogle ScholarPubMed
22.Davis, J, Barter, J, Kane, JM. Antipsychotic drugs. In: Kaplan, HI and Sadock, BJ, eds. Comprehensive Textbook of Psychiatry. 5th ed. Baltimore, Md: Williams & Wilkins; 1989:1591–1626.Google Scholar
23.Harrison, TS, Goa, KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004;18(2):113–132.CrossRefGoogle ScholarPubMed
24.Siegel, SJ, Winey, KI, Gur, RE, et al.Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology. 2002;26(6):817–823.CrossRefGoogle ScholarPubMed
25.Irani, F, Dankert, M, Brensinger, C, et al.Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology. 2004;29(5):960–968.Google Scholar